Tegsedi-Induced Warm Antibody Autoimmune Hemolytic Anemia

Abstract

Autoimmune hemolytic anemia is a hemolytic disorder in which antibodies attack erythrocytes, causing their destruction. Many medications have been linked to autoimmune hemolytic anemia, such as antibiotics, chemotherapy agents, and nonsteroidal anti-inflammatory drugs. Inotersen (Tegsedi [Sobi]) is a medication used for stage 1 or stage 2 polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis. It limits production and deposition of the transthyretin protein. Serious adverse effects include anemia, thrombocytopenia, and glomerulonephritis. We present a case of warm antibody autoimmune hemolytic anemia in a patient with hereditary transthyretin-mediated amyloidosis on Tegsedi that has not yet been reported in current literature, to our knowledge. This finding establishes the importance of continuous laboratory monitoring when administering this medication.